Robert Renninger - Oct 1, 2024 Form 3 Insider Report for Athira Pharma, Inc. (ATHA)

Role
VP of Finance
Signature
s/ Mark Worthington, Attorney-in-Fact for Robert Renninger
Stock symbol
ATHA
Transactions as of
Oct 1, 2024
Transactions value $
$0
Form type
3
Date filed
10/3/2024, 07:05 PM

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding ATHA Common Stock 76.6K Oct 1, 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding ATHA Stock Option (Right to Buy) Oct 1, 2024 Common Stock 18.9K $17.00 Direct F1
holding ATHA Stock Option (Right to Buy) Oct 1, 2024 Common Stock 1.09K $22.22 Direct F2
holding ATHA Stock Option (Right to Buy) Oct 1, 2024 Common Stock 10K $21.15 Direct F3
holding ATHA Stock Option (Right to Buy) Oct 1, 2024 Common Stock 13K $12.38 Direct F4
holding ATHA Stock Option (Right to Buy) Oct 1, 2024 Common Stock 40.6K $10.64 Direct F5
holding ATHA Stock Option (Right to Buy) Oct 1, 2024 Common Stock 56.8K $3.37 Direct F6
holding ATHA Stock Option (Right to Buy) Oct 1, 2024 Common Stock 74.2K $3.26 Direct F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 One-fourth of the shares subject to the option vested on July 6, 2021 and one-fourth of the shares subject to the option vest on each year thereafter.
F2 One-fourth of the shares subject to the option vested on July 6, 2021 and one-fourth of the shares subject to the option vest on each year thereafter.
F3 One-fourth of the shares subject to the option vested on January 8, 2022 and one-fourth of the shares subject to the option vest on each year thereafter.
F4 One-fourth of the shares subject to the option vested on December 1, 2022 and one-fourth of the shares subject to the option vest on each year thereafter.
F5 One forty-eighth (1/48th) of the shares subject to the option vested on February 18, 2022 and one forty-eighth of the shares subject to the option will vest each month thereafter.
F6 One thirty-sixth (1/36th) of the shares subject to the option vested on February 19, 2023 and one thirty-sixth of the shares subject to the option vest each month thereafter.
F7 One forty-eighth (1/48th) of the shares subject to the option vested on March 14, 2024 and one forty-eighth of the shares subject to the option will vest each month thereafter.

Remarks:

Power of Attorney enclosed